Mucormycosis in patients with hematological diseases: seven cases reports and literature review
10.3760/cma.j.issn.0253-2727.2019.11.011
- VernacularTitle: 血液病合并毛霉菌病七例报道并文献复习
- Author:
Yao QI
1
;
Mingfeng ZHAO
;
Qi DENG
;
Li GENG
Author Information
1. Department of Hematology, Tianjin First Central Hospital, The First Central Clinical College of Tianjin Medical University 300192, China
- Publication Type:Journal Article
- Keywords:
Hematological diseases;
Mucormycosis;
Treatment outcome
- From:
Chinese Journal of Hematology
2019;40(11):943-947
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the clinical characteristics, diagnosis, treatment and prognosis of patients with hematological diseases that complicated by mucormycosis, and to improve the understanding and clinical diagnosis and treatment of the disease.
Methods:The clinical data of 7 patients suffering from mucormycosis during September 2012 and September 2018 were retrospectively analyzed, and their clinical characteristics, treatment process and prognosis were analyzed.
Results:Of 7 patients, there were 4 males and 3 females, with a median age of 36 (19-79) years old. Two patients were diagnosed as acute myeloid leukemia as the underlying disease, the other 5 patients suffered from acute B lymphoblastic leukemia, peripheral T cell lymphoma, chronic myelocytic leukemia in blastic phase, myeloproliferative neoplasm and severe aplastic anemia after transplantation, respectively. Among them, disease types of mucormycosis were pulmonary in 4 patients, rhino-orbital-cerebral in 1 patient, cutaneous in 1 patient and disseminated in 1 patient. All the cases were confirmed by biopsy histopathology. The treatment drugs were amphotericin B or liposomal amphotericin B, and posaconazole. Surgical treatment was performed in 4 patients, 3 out of 4 achieved radical debridement, and the other one had local debridement. Two patients were cured, 1 patient was improved and 4 patients died.
Conclusions:The clinical manifestation and image feature of mucormycosis in patients with hematological diseases were diverse, and the mortality rate is high, diagnosis mainly depends on histopathology. Early diagnosis, control of underlying disease, improvement of immunosuppressive status, timely effective antifungal therapy and radical surgical debridement are the key points for improving the survival rate of patients with hematological diseases complicated by mucormycosis.
